ArticlePharmaceutics2024
Integrated QSAR Models for Prediction of Serotonergic Activity: Machine Learning Unveiling Activity and Selectivity Patterns of Molecular Descriptors.
Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Explainable Artificial Intelligence (xAI) for 5-HTMolecules (Basel, Switzerland) · 2026Article
- Interpretable Quantitative Structure-Activity Relationship (QSAR) for identification of potent antifungal activity agents towards Candida albicans ATCC 2091.Molecular diversity · 2026Article
- Prediction of Activity and Selectivity Profiles of Sigma Receptor Ligands Using Machine Learning Approaches.Journal of chemical information and modeling · 2025Article
- Explainable Artificial Intelligence in the Field of Drug Research.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Understanding the features of compounds that determine their high serotonergic activity and selectivity for specific receptor subtypes represents a pivotal challenge in drug discovery, directly impacting the ability to minimize adverse events while maximizing therapeutic efficacy. Up to now, this process has been a puzzle and limited to a few serotonergic targets. One approach represented in the literature focuses on receptor structure whereas in this study, we followed another strategy by creating AI-based models capable of predicting serotonergic activity and selectivity based on ligands' representation by molecular descriptors. Predictive models were developed using Automated Machine Learning provided by Mljar and later analyzed through the SHAP importance analysis, which allowed us to clarify the relationship between descriptors and the effect on activity and what features determine selective affinity for serotonin receptors. Through the experiments, it was possible to highlight the most important features of ligands based on highly efficient models. These features are discussed in this manuscript. The models are available in the additional modules of the SerotoninAI application called "Serotonergic activity" and "Selectivity".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.